Ann MacLaren

Ann MacLaren

Company: Triphase Accelerator

Job title: Executive Director, Translational Development


Highlighting the Phase 1 Pharmacokinetics & Safety Study of TRPH-222 in Patients with Relapsed/ Refractory B-cell Non-Hodgkin Lymphoma 12:00 pm

Summarise the SMARTag technology and Phase 1 study design Review of the safety and efficacy of TRPH-222 in R/R NHL Presenting our thoughts on future directions for ADCs using novel payload linkers and moving beyond cytotoxic payloadsRead more

day: Track C - Day 2

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.